Table 1 Activity of therapeutic antibodies against B.1, Delta and Omicron BA.1, BA.2 and BA.5 variants.

From: In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5

Antibody

Strain

BavPat B.1

Delta

BA.1

BA.2

BA.5

GSK/ Vir

Sotrovimab (vir-7831)

EC50

46.0

51.5

315.6

441.0

858.2

MNU50

72.4

64.7

10.6

7.6

3.9

fold-change

–

1.1

6.9

9.6

18.7

AstraZeneca

Cilgavimab (AZD1061)

EC50

19.2

40.3

1617.0

49.8

23.5

MNU50

52.1

24.8

0.6

20.1

42.6

fold-change

-

2.1

84.2

2.6

1.2

Tixagevimab (AZD8895)

EC50

18.3

17.2

n.n

n.n

n.n

MNU50

54.7

58.1

n.n

n.n

n.n

fold-change

–

0.9

–

–

–

Evusheld (AZD7442)

EC50

20.2

24.7

594.6

37.4

56.6

MNU50

99.0

80.8

3.4

53.5

35.3

fold-change

–

1.2

29.4

1.9

2.8

  1. Interpolated EC50 values are expressed in ng/mL. For B.1, BA.1 and BA.2 strains, the EC50 is the mean of two independent experiment (n = 2), each including three replicates. (n.n: non-neutralising). MNU50: neutralizing capacity per treatment expressed in million units. One unit is defined as the amount of a given antibody needed to provide 50% neutralization of 100 TCID50 of a given strain. Doses refer to treatments authorized in the European Union (Sotrovimab: 500 mg IV21; AZD7442: 300 mg IM (Cilgavimab 150 mg + Tixagevimab 150 mg). Fold change reduction were calculated in comparison with the ancestral B.1 strain.
Back to article page